{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:22:43Z","timestamp":1780348963746,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H00294"],"award-info":[{"award-number":["21H00294"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05300"],"award-info":[{"award-number":["19H05300"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ae0121024"],"award-info":[{"award-number":["JP21ae0121024"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ae0121022"],"award-info":[{"award-number":["JP21ae0121022"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012044","name":"Kwansei Gakuin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102756","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:09:41Z","timestamp":1761898181000},"page":"102756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antisense oligonucleotide targeting the E3 ligase RFFL potentiates CFTR modulator efficacy in CF primary bronchial epithelial cells"],"prefix":"10.1016","volume":"36","author":[{"given":"Daichi","family":"Hinata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuya","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuyuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Obika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-2224","authenticated-orcid":false,"given":"Tsukasa","family":"Okiyoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102756_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic Fibrosis: A Review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102756_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2025.102756_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin-proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102756_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102756_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"Bardin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102756_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102098","article-title":"Small-molecule drugs for cystic fibrosis: Where are we now?","volume":"72","author":"Laselva","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2025.102756_bib7","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/acs.jmedchem.4c02547","article-title":"Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102756_bib8","article-title":"A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.omtn.2025.102756_bib9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102756_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","article-title":"Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase","volume":"44","author":"Okiyoneda","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2025.102756_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.840649","article-title":"The Ubiquitin Ligase RNF34 Participates in the Peripheral Quality Control of CFTR (RNF34 Role in CFTR PeriQC)","volume":"9","author":"Taniguchi","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtn.2025.102756_bib12","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fphar.2018.01100","article-title":"Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer","volume":"9","author":"Fukuda","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102756_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150433","article-title":"Enhanced CFTR modulator efficacy in \u0394F508 CFTR mouse organoids by ablation of RFFL ubiquitin ligase","volume":"733","author":"Hinata","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102756_bib14","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.omtn.2025.102756_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis","volume":"2","author":"Awatade","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtn.2025.102756_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102756_bib17","series-title":"Bridged Nucleic Acids for Therapeutic Oligonucleotides","author":"Islam","year":"2023"},{"key":"10.1016\/j.omtn.2025.102756_bib18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","article-title":"A Review on Commercial Oligonucleotide Drug Products","volume":"113","author":"Vinjamuri","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omtn.2025.102756_bib19","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102756_bib20","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/cbic.201200506","article-title":"Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency","volume":"13","author":"Yahara","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.omtn.2025.102756_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.omtn.2020.10.001","article-title":"Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting","volume":"22","author":"Kanda","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102756_bib22","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","article-title":"Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting \u03b1-synuclein as a novel therapy for Parkinson's disease","volume":"9","author":"Uehara","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102756_bib23","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/s41416-024-02859-5","article-title":"Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer","volume":"131","author":"Kanda","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102756_bib24","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1038\/s41467-019-11533-x","article-title":"GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGF\u03b2 signaling","volume":"10","author":"Matsumoto","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102756_bib25","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1038\/s41598-019-43100-1","article-title":"A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer","volume":"9","author":"Shimojo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102756_bib26","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/nar\/gkg599","article-title":"Vienna RNA secondary structure server","volume":"31","author":"Hofacker","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102756_bib27","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102756_bib28","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1093\/nar\/gku142","article-title":"Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides","volume":"42","author":"Burdick","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102756_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nature14138","article-title":"Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9","volume":"520","author":"Ohto","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102756_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.omtn.2025.102756_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv626","article-title":"Ca2+ enrichment in culture medium potentiates effect of oligonucleotides","volume":"43","author":"Hori","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102756_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102756_bib33","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.167.7.3555","article-title":"Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells","volume":"167","author":"Takeshita","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102756_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2567.2004.01962.x","article-title":"Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation","volume":"113","author":"Vollmer","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.omtn.2025.102756_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/nat.2022.0034","article-title":"Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab Cells","volume":"32","author":"Pollak","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102756_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61666-3","article-title":"Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation","volume":"14","author":"Yoshida","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102756_bib37","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102756_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102756_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102756_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2025.102756_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115730","article-title":"Identification of \u03b1-Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis","volume":"215","author":"Taniguchi","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102756_bib42","doi-asserted-by":"crossref","first-page":"R15-R19","DOI":"10.1016\/j.cub.2008.11.040","article-title":"CARP2 deficiency does not alter induction of NF-kappaB by TNFalpha","volume":"19","author":"Ahmed","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.omtn.2025.102756_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102756_bib44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1083\/jcb.200312018","article-title":"Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes","volume":"164","author":"Sharma","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102756_bib45","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800172","article-title":"Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants","volume":"2","author":"van Willigen","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omtn.2025.102756_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2025.102756_bib47","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ceb.2011.04.012","article-title":"Protein quality control at the plasma membrane","volume":"23","author":"Okiyoneda","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102756_bib48","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1073\/pnas.0307459101","article-title":"Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth","volume":"101","author":"McDonald","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102756_bib49","doi-asserted-by":"crossref","first-page":"33978","DOI":"10.1074\/jbc.M113.477406","article-title":"Different Raf protein kinases mediate different signaling pathways to stimulate E3 ligase RFFL gene expression in cell migration regulation","volume":"288","author":"Gan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102756_bib50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1158\/1541-7786.MCR-13-0061","article-title":"Tumor suppressor functions of miR-133a in colorectal cancer","volume":"11","author":"Dong","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102756_bib51","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M610793200","article-title":"CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102756_bib52","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1021\/acs.jproteome.5c00086","article-title":"Quantitative Proteomic Analysis Reveals JMJD6 and DNAJB11 as Endogenous Substrates of E3 Ligase RFFL","volume":"24","author":"Narendradev","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.omtn.2025.102756_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1370676","article-title":"Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters","volume":"15","author":"Taniguchi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102756_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152251","article-title":"RFFL inhibition increases cell surface CFTR and reduces IL-8 production in airway epithelial cells upon COPD-associated environmental pathogen exposure","volume":"777","author":"Hinata","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102756_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102756_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-61779-117-8_4","article-title":"Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators","volume":"741","author":"Neuberger","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102756_bib57","first-page":"7454","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","volume":"48","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:09:57Z","timestamp":1766196597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003105"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102756","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotide targeting the E3 ligase RFFL potentiates CFTR modulator efficacy in CF primary bronchial epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102756"}}